Dr. Wu has over 30 years of experience in the field of CMC. He joined BC as the chief technology officer in January 2020, which position he held until April 2023, and served as the general manager of BC's Cangzhou branch from January 2020 to October 2020. He was further appointed as vice president in December 2020, which position he held until April 2023.

Prior to joining BC, Dr. Wu served as a vice president of the Active Pharmaceutical Ingredient (API) division of Zhejiang Huahai Pharmaceutical Co. Ltd. (Zhejiang Huahai") from February 2019 to September 2019, as a technical consultant of Shandong Lixin Pharmaceuticals Co. Ltd. from January 2018 to February 2019, as the general manager of Teva Pharmaceutical & Chemical (Hangzhou) Co.

Ltd. from November 2016 to January 2018, as the general manager of Xellia (Taizhou) Pharmaceutical Co. Ltd. from April 2014 to November 2016, as the vice president of Lianhe Chemical Technology Co. Ltd. from June 2011 to March 2013 and as the executive director in API production technology of Zhejiang Huahai from April 2010 to June 2011.

Dr. Wu has also had extensive experience in R&D in the pharmaceutical industry, which includes his research experience at Wyeth Holdings Corporation, Honeywell International Inc. (formerly known as AlliedSignal Inc.), Rohm and Haas Company and the Virginia Polytechnic Institute and State University. Dr. Wu obtained his bachelor's degree in polymer chemistry from University of Science and Technology of China in the PRC in July 1983. He further obtained his doctoral degree in chemistry from University of Maryland, College Park in December 1989.

He obtained his MBA certificate from Tulane University in April 2004. He obtained the qualification of professor-level senior engineer from Zhejiang Province Human Resources and Social Security Department in June 2015. Han Ying, Ph.D. (Age 58).

Dr. Ying currently serves as a director of the Gene Corporation and as a director of Base Therapeutics. Dr. Ying has served as the co-founder and chief operating officer of Base Therapeutics since 2021. From 2020 to 2021, he served as the chief technology officer for Tactiva Therapeutics.

From 2017 to 2019, Dr. Ying served as the scientific founding team member for T-Cure Bioscience and as chief scientific officer in the in the biomedical sector of Sanpower Group. From 1999 to 2022, Dr. Ying served as a principal investigator at the Maxine Dunitz Neurosurgical Institute, where he oversaw a clinical laboratory conducting dendritic cell vaccine trials for malignant brain tumors. From 2002 to 2007, he served as a project leader in the Cancer Research Department of Berlex Biosciences.

From 2007 to 2009, Dr. Ying was at Monogram Biosciences, a personalized medicine company that developed biomarkers for a selection of patients for novel targeted drugs. In 2012, Dr. Ying co-founded Immunnova, a biotech company focused on dendritic cell vaccines and antigen-specific T cells. He has consulted for several early and late-stage biotech companies in the field of cancer immunotherapy, including HRYZ, Sanpower Group and SinoBioway, and he served as the key technical expert for the international mergers and acquisitions team that completed the acquisition of Dendreon by Sanpower Group in 2017.

Dr. Ying received his Ph.D. in cancer biology from Stanford University and his B.S. and M.S. in biological studies from Beijing University. He completed his post-doctoral training at the National Cancer Institute. On October 30, 2023, Nassim Usman, Ph.D., Renate Parry, Ph.D. and Han Ying, Ph.D. were appointed to the Audit Committee of the Board, and Nassim Usman, Ph.D. was appointed the chair of the Audit Committee.

The Board has determined that (i) each of Nassim Usman, Ph.D., Renate Parry, Ph.D. and Han Ying, Ph.D. is independent under applicable Nasdaq listing standards and Rule 10A-3(b)(1) of the Securities Exchange Act of 1934, as amended (the Exchange Act"); (ii) Nassim Usman, Ph.D. is an audit committee financial expert" within the meaning of the SEC regulations; and (iii) each member of the Audit Committee has the requisite financial expertise required under the applicable requirements of Nasdaq. In arriving at this determination, the Board examined each Audit Committee member's scope of experience and the nature of their employment. On October 30, 2023, Nassim Usman, Ph.D., Han Ying, Ph.D., Gordon G. Carmichael, Ph.D. and Renate Parry, Ph.D. were appointed to the Compensation Committee of the Board (the Compensation Committee"), and Han Ying, Ph.D. was appointed the chair of the Compensation Committee.

The Board has determined that each member is independent under applicable Nasdaq listing standards and is a non-employee director" as defined in Rule 16b-3 promulgated under the Exchange Act. On October 30, 2023, Ying Luo, Ph.D., Thomas Eastling and Gordon G. Carmichael were appointed to the Nominating and Corporate Governance Committee of the Board (the Nominating Committee"), and Ying Luo, Ph.D. was appointed the chair of the Nominating Committee. The Board has determined that Gordon G. Carmichael, Ph.D. is independent, and Ying Luo, Ph.D. and Thomas Eastling are not independent under applicable Nasdaq listing standards.

Gyre is relying on the exception available for controlled companies" under which it is not required to have a nominating committee comprised entirely of independent directors within the meaning of applicable Nasdaq listing standards. On October 30, 2023, immediately prior to and effective upon the Closing, Nassim Usman, Ph.D., Catalyst's President and Chief Executive Officer, ceased to be an officer of Gyre but is remaining a director of Gyre. Catalyst previously entered into an offer letter with Dr. Usman, pursuant to which he became eligible to receive severance benefits upon a qualifying termination of employment.

On October 30, 2023, immediately prior to and effective upon the Closing, Seline Miller, Catalyst's Interim Chief Financial Officer, ceased to be an officer of Gyre. Ms. Miller has agreed to provide consulting services regarding matters relating to Gyre's accounting practices and financial reporting from the Closing until March 31, 2024.